Sandi See Tai

Company: Lexeo Therapeutics

Job title: Chief Development Officer

Seminars:

Demonstrating a Precision Medicine Approach to Targeting APOE4 Homozygotes to Treat the Multivariate Pathologies of Alzheimer’s Disease 11:30 am

Outlining the rationale for using APOE2 to develop a more specific genetic medicine Showcasing the ability of LX1001 to supplement levels of APOE2 Reviewing the clinical data across all four dose cohortsRead more

day: Conference Day Two - Track Two